XML 106 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2019
Jun. 30, 2019
Current assets:    
Cash and cash equivalents $ 81.2 $ 93.2
Marketable investment securities 60.4 43.7
Prepaid expenses 16.2 16.6
Inventory 28.1 31.4
Trade accounts receivable 118.3 133.9
Prepaid taxes 24.7 25.1
Other receivables 3.5 4.7
Assets held for sale 32.9  
Total current assets 365.3 348.6
Property, plant and equipment, net 36.5 57.3
Operating lease right-of-use assets 67.3  
Long-term marketable investment securities 47.6 54.9
Intangibles, net 653.5 684.7
Goodwill 408.1 417.2
Total assets 1,578.3 1,562.7
Current liabilities:    
Accounts payable 21.0 33.3
Accrued liabilities 61.1 78.9
Current maturities of operating lease liabilities 12.8  
Short-term contingent consideration 3.4 3.4
Deferred revenue 3.6 2.2
Liabilities held for sale 10.5  
Total current liabilities 112.4 117.8
Unrecognized tax benefits 22.4 21.7
Noncurrent operating lease liabilities 58.7  
Other long-term liabilities   7.8
Contingent consideration 6.9 10.4
Long-term debt 225.1 233.5
Long-term deferred taxes 75.5 82.6
Total liabilities 501.0 473.8
Commitments and contingencies
Stockholders’ equity:    
Common stock, 74.5 and 73.5 shares outstanding at December 31, 2019 and June 30, 2019 respectively 0.7 0.7
Additional paid-in capital 1,085.1 1,068.0
Accumulated other comprehensive loss (5.3) (5.4)
Retained earnings (deficit) (3.3) 25.6
Total Myriad Genetics, Inc. stockholders’ equity 1,077.2 1,088.9
Non-Controlling Interest 0.1  
Total stockholders' equity 1,077.3 1,088.9
Total liabilities and stockholders’ equity $ 1,578.3 $ 1,562.7